| 51 |
35081725 | Novel mutation signatures in the prognosis of EGFR-TKIs targeted therapy for non-small cell lung cancer patients based on the 1000-gene panel sequencing. | 2022 Mar |
1 |
| 52 |
35088537 | Durable response to durvalumab-based immunochemotherapy in small-cell lung carcinoma transformation from EGFR-mutant non-small cell lung cancer: A case report. | 2022 Mar |
2 |
| 53 |
35102249 | Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. | 2022 Mar |
5 |
| 54 |
35105467 | [Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma]. | 2022 Mar |
1 |
| 55 |
35106279 | Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report. | 2022 |
4 |
| 56 |
35112017 | Non-small cell lung cancer with iris metastasis controlled with osimertinib and monthly intravitreal bevacizumab. | 2022 Mar |
1 |
| 57 |
35119858 | Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation. | 2022 Feb 28 |
2 |
| 58 |
35144338 | [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis]. | 2022 Feb 15 |
1 |
| 59 |
35146920 | Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report. | 2022 Apr |
2 |
| 60 |
35156036 | Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. | 2022 Jan-Dec |
2 |
| 61 |
35159036 | Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF). | 2022 Feb 2 |
1 |
| 62 |
35168607 | Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis. | 2022 Feb 15 |
2 |
| 63 |
35173881 | Efficacy and mechanism of osimertinib combined with bevacizumab in the treatment of postoperative EGFR positive stage II-IIIA lung adenocarcinoma. | 2022 |
2 |
| 64 |
35189835 | Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters. | 2022 Feb 21 |
1 |
| 65 |
35194503 | Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy. | 2022 Jan-Mar |
3 |
| 66 |
35197546 | Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling. | 2022 Feb 23 |
2 |
| 67 |
35201951 | Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status. | 2022 Jan-Dec |
3 |
| 68 |
35208635 | Successful Management of Osimertinib-Induced Heart Failure. | 2022 Feb 18 |
3 |
| 69 |
35242623 | TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. | 2022 Jan |
1 |
| 70 |
35245845 | EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature. | 2022 Apr |
2 |
| 71 |
35251316 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. | 2022 |
1 |
| 72 |
35257278 | Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B). | 2022 Apr |
1 |
| 73 |
35261905 | Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report. | 2022 Jan |
2 |
| 74 |
35265776 | Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer. | 2022 Jun |
4 |
| 75 |
35266116 | MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review. | 2022 Mar |
3 |
| 76 |
35287683 | Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer. | 2022 Mar 14 |
2 |
| 77 |
35293747 | Mapping Tyrosine Kinases Based on a TK Activity-Representing Peptide Library Reveals a Role for SRC in H1975 Drug Resistance. | 2022 Apr 1 |
1 |
| 78 |
35294773 | ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer. | 2022 Jun |
1 |
| 79 |
35323965 | Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial). | 2022 Mar 22 |
1 |
| 80 |
35343187 | Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India. | 2022 Mar |
3 |
| 81 |
35344648 | Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. | 2022 Mar 28 |
4 |
| 82 |
35347039 | Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations. | 2022 Apr |
2 |
| 83 |
35347108 | Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. | 2022 Mar 28 |
1 |
| 84 |
35348294 | Rare ashy dermatosis-like hyperpigmentation associated with osimertinib. | 2022 May |
1 |
| 85 |
35365042 | A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report. | 2022 Mar |
6 |
| 86 |
35365043 | Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review. | 2022 Mar |
7 |
| 87 |
35378738 | Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review. | 2022 Jun |
3 |
| 88 |
35379563 | An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. | 2022 Apr 2 |
1 |
| 89 |
35386002 | First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study. | 2022 Apr 6 |
2 |
| 90 |
35399244 | Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation. | 2022 Mar |
1 |
| 91 |
35399574 | EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature. | 2022 Mar |
1 |
| 92 |
35402377 | Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer. | 2022 |
2 |
| 93 |
35412115 | Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. | 2022 Apr |
6 |
| 94 |
35431558 | Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer. | 2022 |
4 |
| 95 |
35431966 | Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial. | 2022 |
1 |
| 96 |
35445633 | Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences. | 2022 Apr 26 |
2 |
| 97 |
35446957 | First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. | 2022 Apr 22 |
2 |
| 98 |
35449204 | Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. | 2022 Apr 21 |
3 |
| 99 |
35461372 | Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction. | 2022 Apr 23 |
1 |
| 100 |
35462930 | Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports. | 2022 |
3 |